BRIEF — Pharming Presents Positive Phase II Topline Data For Leniolisib

Oct 14 (Reuters) — Pharming Group N.V.: Presents Positive Phase Ii Topline Data For Leniolisib In Genetic Pids With Immune Dysregulation At Esid 2026 Leniolisib Well-tolerated With Benefits In Immune Dysregulation Measures Mean Spleen Volume Reduction Of 26.4% In Phase Ii Leniolisib Trial Improvement In Liver Stiffness Observed In Phase Ii Leniolisib Trial Mean Lymph Node Lesion Size Reduction Of 33.7% In Phase Ii Leniolisib Trial Mean Dlco Increased By 8.0% In Phase Ii Leniolisib Trial All Phase Ii Leniolisib Study Completers Enrolled In Three-year Extension Study Leniolisib Was Generally Well-tolerated Across All 4 Genotypes Topline Results From Separate Phase Ii Trial In Cvid Expected In November Source text:... Further company coverage: PHAR.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;)